DHA‐P versus Artemether plus amodiaquine
Trial ID	Sample Size	Blinding	Clinical symptoms monitoring	Biochemistry	Haematological	ECG
Hasugian 2007 IDN	334	Open label	Clinical assessment daily until afebrile then weekly until day 42.	None	None	None
Karema 2006 RWA	504	Open label	Clinical assessment on days 0, 1, 2, 3, 7, 14, 21, and 28.	Differential WBC count (and LFT at one site only) at days 0 and 14	None	None
Smithuis 2010 MMR	316	Open label	Review weekly for 9 weeks.	None	None	None
The 4ABC Study 2011 AF	2477	Single blind	Clinical assessment on days 1, 2, 3, 7, 14, 21, and 28.	Liver and renal function tests at days 7 and 28	FBC at days 3, 7, 14, and 28	None